The cornerstone of this strategic offensive is the drug Tirzepatide, a compound already achieving blockbuster status in other global markets for treating Type 2 diabetes and obesity. Under the brand ...

On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...

Net profit of Shanthi Gears declined 16.07% to Rs 21.51 crore in the quarter ended September 2025 as against Rs 25.63 crore during the pre ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...

Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Shares of Cipla fell more than 3 per cent on Friday after the drugmaker announced a partnership with US pharmaceutical major ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

The multiple 'large' orders of L&T include a contract with Hindalco for the construction of a 180 KTPA Aluminium Smelter ...

Good morning and welcome to the Ryder System third Quarter 2025 Earnings Release Conference Call. [Operator Instructions] Today's call is being recorded. If you have any objections, please disconnect ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...